Key View

• FDA approval of Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys will support unmet need as the first gene therapy approved to treat the disease.
• We expect Elevidys will be covered by insurance given its high cost, with the decision likely to be sped up by the short treatment window for those currently eligible.
• Sales

Key View

• The US dollar will remain the pre-eminent global currency for the foreseeable future, even as various economies look to diversify their reserve holdings and settle bilateral trade in an increasingly wide range of currencies.
• While the US dollar’s role will continue to decline over the coming years, it will be a slow erosion, rather

Key View:

• Strong demand from fleet buyers will drive higher output growth in the passenger car segment than previously expected.
• We maintain our view that this begins a period of more sustained car production growth as electrification drives more interest in the segment.
• Light truck production will continue to outperform as it is the segment

Key View

• We have revised up our forecast for US real GDP growth in 2023 from 1.0% to 1.4% (consensus: 1.0%), which we expect will be followed by a 0.6% (previously: 1.0%, consensus: 0.8%) expansion in 2024.
• Given the strength of incoming data, we now anticipate that the US will avoid falling into what we continue to believe will be a light

Key View: The announcement of Walmart's new beef processing facility on June 13 2023, points to how the retailer is looking to take advantage of trends in the US beef market. While all indicators point to a long-term downward trajectory in consumer spending on red meat, there are still strong growth opportunities to take advantage of in the US’

Key View

• On June 7 2023, Google Cloud announced a collaboration with Mayo Clinic to utilise generative AI within healthcare.
• We expect to see more companies leveraging generative AI to improve the way healthcare is delivered.
• Further research is required for widespread use of generative AI in healthcare to ensure maximum accuracy.
• Patient

Key View

• We now expect the US Appalachian Basin to see stronger natural gas production growth in 2024 on the back of the planned expansion of exit capacity from the gas-rich basin through the completion of the Mountain Valley Pipeline scheduled for H223.
• However, weakening drilling activity across other gas-rich regions in the US will weigh

Key View

• Grail reported positive data from an observational study of its multi-cancer early detection test, Galleri, at the 2023 American Society of Clinical Oncology.
• We believe this positive data bodes well for Galleri FDA approval, which is expected over the near term.
• The ongoing antitrust battle between the US Federal Trade Commision

Key View

• Amyotrophic lateral sclerosis (ALS) patients will continue to be underserved given current lack of effective treatments.
• Drug trial failures may discourage pharmaceutical companies from investing in new ALS treatments, given their high cost and legnthy duration.
• Although some treatments will likely fail, we expect the approval of